Endo International PLC (ENDP) Receives Average Recommendation of “Hold” from Analysts
Endo International PLC (NASDAQ:ENDP) (TSE:ENL) has been given an average recommendation of “Hold” by the twenty-four research firms that are currently covering the stock, Marketbeat reports. Four analysts have rated the stock with a sell recommendation, fifteen have assigned a hold recommendation and five have assigned a buy recommendation to the company. The average 12-month target price among brokers that have covered the stock in the last year is $11.65.
ENDP has been the topic of several research analyst reports. Oppenheimer Holdings, Inc. reissued a “hold” rating on shares of Endo International PLC in a report on Sunday, July 23rd. ValuEngine lowered Endo International PLC from a “buy” rating to a “hold” rating in a report on Friday, September 1st. Zacks Investment Research raised Endo International PLC from a “hold” rating to a “buy” rating and set a $9.75 price objective on the stock in a report on Wednesday, October 11th. Royal Bank Of Canada set a $9.00 price objective on Endo International PLC and gave the company a “hold” rating in a report on Tuesday, October 17th. Finally, BidaskClub raised Endo International PLC from a “sell” rating to a “hold” rating in a report on Wednesday, July 19th.
TRADEMARK VIOLATION WARNING: This piece was published by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at https://www.watchlistnews.com/endo-international-plc-endp-receives-average-recommendation-of-hold-from-analysts/1707773.html.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. HL Financial Services LLC boosted its stake in Endo International PLC by 1.0% during the second quarter. HL Financial Services LLC now owns 52,800 shares of the company’s stock worth $590,000 after buying an additional 500 shares during the last quarter. Meeder Asset Management Inc. boosted its stake in Endo International PLC by 1.4% during the second quarter. Meeder Asset Management Inc. now owns 48,699 shares of the company’s stock worth $544,000 after buying an additional 677 shares during the last quarter. Capstone Asset Management Co. boosted its stake in Endo International PLC by 3.1% during the second quarter. Capstone Asset Management Co. now owns 32,035 shares of the company’s stock worth $358,000 after buying an additional 960 shares during the last quarter. Arizona State Retirement System boosted its stake in Endo International PLC by 1.5% during the second quarter. Arizona State Retirement System now owns 83,700 shares of the company’s stock worth $935,000 after buying an additional 1,200 shares during the last quarter. Finally, Oakbrook Investments LLC boosted its stake in Endo International PLC by 8.2% during the second quarter. Oakbrook Investments LLC now owns 17,100 shares of the company’s stock worth $191,000 after buying an additional 1,300 shares during the last quarter. 90.50% of the stock is currently owned by institutional investors.
Shares of Endo International PLC (NASDAQ:ENDP) traded up $0.03 during mid-day trading on Thursday, reaching $7.02. The company had a trading volume of 6,398,900 shares, compared to its average volume of 7,343,842. The company has a debt-to-equity ratio of 10.78, a quick ratio of 0.86 and a current ratio of 1.08. The stock has a market capitalization of $1,570.00, a PE ratio of 1.44, a P/E/G ratio of 1.90 and a beta of 0.53. Endo International PLC has a 52 week low of $5.77 and a 52 week high of $18.05.
Endo International PLC (NASDAQ:ENDP) (TSE:ENL) last announced its quarterly earnings results on Thursday, November 9th. The company reported $0.91 earnings per share for the quarter, beating the consensus estimate of $0.85 by $0.06. The company had revenue of $786.90 million during the quarter, compared to analysts’ expectations of $794.93 million. Endo International PLC had a positive return on equity of 66.98% and a negative net margin of 126.97%. Endo International PLC’s quarterly revenue was down 11.0% on a year-over-year basis. During the same period last year, the business earned $1.01 earnings per share. research analysts anticipate that Endo International PLC will post 3.67 EPS for the current year.
Endo International PLC Company Profile
Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.
Receive News & Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.